Olivamine and Stem Cell Wound Closure Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing methods are ineffective for chronic wounds such as pressure ulcers, diabetic ulcers, and venous ulcers, which often get trapped in the inflammation phase and require excessive time to heal, leading to secondary complications like tissue damage and mortality.
Innovation Solution
A combination of hydroxytyrosol and oleuropein, along with umbilical cord blood stem cells, is administered topically to accelerate wound closure and promote neurovascularization, significantly reducing the time required for wound healing by enhancing cellular migration and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If umbilical cord blood stem cells alone are used for wound healing, then some wound repair occurs, but the healing time is excessively long and wounds get trapped in inflammation phase
Solution Approach 1:
The patent combines hydroxytyrosol and oleuropein with umbilical cord blood stem cells in a single topical composition. This merging of multiple active components creates a synergistic effect where the phenolic compounds enhance the stem cells' ability to promote angiogenesis and reduce inflammation, thereby accelerating wound closure while maintaining reliability.
Solution Approach 2:
The invention uses a composite formulation containing hydroxytyrosol, oleuropein, and umbilical cord blood stem cells together. This composite material leverages the complementary mechanisms of each component: the antioxidant and anti-inflammatory properties of the phenolic compounds work alongside the regenerative capabilities of the stem cells to overcome the limitations of using stem cells alone.
2Ease of manufacture
If conventional wound healing methods are used for chronic wounds, then standard care is provided, but wounds require excessive time to heal and lead to secondary complications
Solution Approach 1:
The patent changes key parameters of the wound healing process by introducing a topical composition with specific concentrations of hydroxytyrosol and oleuropein alongside stem cells. This parameter change affects the biochemical environment of the wound, promoting faster epithelialization and reducing inflammation duration, thereby improving healing outcomes without significantly complicating the treatment protocol.
3Device complexity
If stem cell therapy is used alone, then cell transplantation is performed, but the therapeutic effect is insufficient for chronic non-healing wounds
Solution Approach 1:
The patent merges stem cell therapy with phenolic compound treatment in a single topical composition. This combination allows the hydroxytyrosol and oleuropein to enhance stem cell survival, proliferation, and differentiation at the wound site, thereby significantly improving wound closure effectiveness for chronic ulcers while maintaining manageable treatment complexity.
Data Source
AI summary
The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood.